论文部分内容阅读
转移性结直肠癌(metastatic Colorectal Cancer,m CRC)患者普遍需要进行KRAS基因突变检测,而当前原发与配对转移肿瘤之间KRAS突变状态一致性存在争议.对原发和配对转移肿瘤KRAS状态进行了meta分析.共纳入44项研究包括2421例配对与转移样本.KRAS基因在原发和配对m CRC间的突变频率高度一致90.67%(38.46%vs 38.87%,OR=0.98,95%CI 0.87~1.10).但KRAS突变状态异质性在配对样本间确实存在.对不同人种进行亚组分析发现亚洲人群中KRAS基因突变状态在原发与配对转移灶间一致性低于欧洲人群(0.85 vs 0.92,χ~2=22.55,P<0.001).因此,在亚洲人群中进行KRAS突变分析时应加以注意.
KRAS gene mutation testing is generally required in patients with metastatic colorectal cancer (mCRC), whereas there is controversy over the consistency of KRAS status between the current primary and paired metastatic tumors. KRAS status of primary and paired metastases Meta-analysis.A total of 44 studies included 2421 paired and metastatic samples.KRAS mutations were highly consistent in the primary and paired mCRCRs with a frequency of 90.67% (38.46% vs 38.87%, OR = 0.98, 95% CI 0.87 ~ 1.10), but heterogeneity of KRAS mutation status did exist between the paired samples.A subgroup analysis of different ethnic groups found that the KRAS gene mutation status in Asian population was less consistent between the primary and paired metastases than the European population (0.85 vs 0.92, χ ~ 2 = 22.55, P <0.001). Therefore, care should be taken when analyzing KRAS mutations in Asian populations.